Doxycycline modulates smooth muscle cell growth, migration, and matrix remodeling after arterial injury

American Journal of Pathology

Volumn 160, Issue 3, 2002, Pages 1089-1095

  Bendeck, Michelle P ^a   Conte, Michelle ^a   Zhang, Mingyu ^a   Nili, Nafiseh ^b   Strauss, Bradley H ^b   Farwell, Stephanie M ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; DOXYCYCLINE; ELASTIN; GELATINASE A; GELATINASE B;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INJURY; ARTERY INTIMA; ARTERY INTIMA PROLIFERATION; ARTERY MEDIA; ARTICLE; ATHEROSCLEROSIS; BALLOON CATHETER; CAROTID ARTERY; CELL DIVISION; CELL GROWTH; CELL MIGRATION; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RAT; RESTENOSIS; TREATMENT OUTCOME; VASCULAR SMOOTH MUSCLE;

EID: 0036118347     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)64929-2     Document Type: Article

References (50)

1. Chemical and biological dynamics of tetracyclines
2. Tetracyclines inhibit connective tissue breakdown by multiple nonantimicrobial mechanisms
3. Matrix metalloproteinases and their inhibition in periodontal treatment
4. Doxycycline inhibition of aneurysmal degeneration in an elastaseinduced rat model of abdominal aortic aneurysm: Preservation of aortic elastin associated with suppressed production of 92 kD gelatinase
5. Pharmacologic suppression of experimental abdominal aortic aneurysms: A comparison of doxycycline and four chemically modified tetracyclines
6. Preoperative treatment with doxycycline reduces aortic wall expression and activation of matrix metalloproteinases in patients with abdominal aortic aneurysms
7. Doxycycline inhibits elastin degradation and reduces metalloproteinase activity in a model of aneurysmal disease
8. Pharmacological effect of tetracyclines on proteoglycanases from interleukin-1-treated articular cartilage
9. Tetracyclines inhibit human synovial collagenase in vivo and in vitro
10. Tetracyclines suppress matrix metalloproteinase activity in adjuvant arthritis and in combination with flurbiprofen, ameliorate bone damage
11. Modification by oral doxycycline administration of articular cartilage breakdown in osteoarthritis
12. In vitro sensitivity of the three mammalian collagenases to tetracycline inhibition: Relationship to bone and cartilage degradation
13. Effects of doxycycline on in vitro growth, migration, and gelatinase activity of breast carcinoma cells
14. Chemically modified tetracyclines inhibit human melanoma cell invasion and metastasis
15. Angiogenesis inhibition by minocycline
16. Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer
17. Selective endothelial growth inhibition by tetracyclines that inhibit collagenase
18. The tetracycline analogs minocycline and doxycycline inhibit angiogenesis in vitro by a non-metalloproteinase-dependent mechanism
19. Inhibition of proliferation and induction of apoptosis by doxycycline in cultured human osteosarcoma cells
20. Tetracycline derivatives induce apoptosis selectively in cultured monocytes and macrophages but not in mesenchymal cells
21. Doxycycline inhibits type X collagen synthesis in avian hypertrophic chondrocyte cultures
22. Doxycycline inhibits collagen synthesis by differentiated articular chondrocytes
23. A novel mechanism of action of tetracyclines: Effects on nitric oxide synthases
24. Chemically modified tetracyclines inhibit inducible nitric oxide synthase expression and nitric oxide production in cultured rat mesangial cells
25. Post-transcriptional regulation of inducible nitric oxide synthase mRNA in murine macrophages by doxycycline and chemically modified tetracyclines
26. Reactive oxygen species activate and tetracyclines inhibit rat osteablast collagenase
27. Roles of infectious agents in atherosclerosis and restenosis
28. Role of matrix metalloproteinases in blood flow-induced arterial enlargement: Interaction with NO
29. Matrix metalloproteinase-2 contributes to ischemia-reperfusion injury in the heart
30. Antibiotics and risk of subsequent first time acute myocardial infarction
31. Kinetics of cellular proliferation after arterial injury. I. Smooth muscle growth in the absence of endothelium
32. Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat
33. Rat carotid neointimal smooth muscle cells re-express a developmentally regulated mRNA phenotype during repair of arterial injury
34. 1 during repair of arterial injury
35. Smooth muscle cell expression of extracellular matrix genes after arterial injury
36. Inhibition of smooth muscle cell proliferation in injured rat arteries. Interaction of heparin with basic fibroblast growth factor
37. Extracellular matrix remodeling after balloon angioplasty injury in a rabbit model of restenosis
38. Characterization of collagen from normal human sclera
39. Activation of recombinant human neutrophil procollagenase in the presence of doxycycline results in fragmentation of the enzyme and loss of enzyme activity
40. Matrix metalloproteinase-8 is expressed in rheumatoid synovial fibroblasts and endothelial cells. Regulation by tumor necrosis factoralpha and doxycycline
41. Doxycycline and chemically modified tetracyclines inhibit gelatinase A (MMP-2) gene expression in human skin keratinocytes
42. Inhibition of epithelial cell matrix metalloproteinases by tetracyclines
43. Inhibition of MMP synthesis by doxycycline and chemically modified tetracyclines (CMTs) in human endothelial cells
44. Transcriptional downregulation of stromelysin by tetracycline
45. Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloproteinase
46. The intima. Soil for atherosclerosis and restenosis
47. Inhibition of matrix metalloproteinase activity inhibits smooth muscle cell migration but not neointimal thickening after arterial injury
48. Regulation of vascular smooth muscle cell migration and proliferation in vitro and in injured rat arteries by a synthetic matrix metalloproteinase inhibitor
49. The synthetic metalloproteinase inhibitor batimastat suppresses injury-induced phosphorylation of MAP kinase ERK1/ERK2 and phenotypic modification of arterial smooth muscle cells in vitro
50. Involvement of extracellular-matrix-degrading metalloproteinases in rabbit aortic smooth-muscle cell proliferation